FibroGen to Report Third Quarter 2024 Financial Results

FGEN 11.04.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Q3 2024 Earnings Call
Full Press ReleaseSEC FilingsOur FGEN Tweets

About Gravity Analytica

Recent News

  • 12.16.2024 - FibroGen Appoints David DeLucia as Chief Financial Officer
  • 11.12.2024 - FibroGen Third Quarter 2024 Earnings Conference Call
  • 11.12.2024 - FibroGen Reports Third Quarter 2024 Financial Results

Recent Filings

  • 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.18.2024 - 3 Initial statement of beneficial ownership of securities
  • 12.16.2024 - 8-K Current report

SAN FRANCISCO,Nov. 04, 2024(GLOBE NEWSWIRE) --FibroGen, Inc.(NASDAQ: FGEN) will announce third quarter 2024 financial results onTuesday, November 12after the market close.FibroGenwill also conduct a conference call on that day at5:00 PM Eastern Timewith the investment community to further detail the company's corporate and financial performance.

Conference Call and WebcastToll-free: 1-877-300-8521International investors: 1-412-317-6026Webcast:Click here

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. A replay of the webcast will also be available for a limited time on the “Events and Presentation” page under the Investors section on theFibroGenwebsite.

About FibroGenFibroGen, Inc.is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved inChina,Europe,Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by theChina Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker, FG-3180. In addition,FibroGenhas expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visitwww.fibrogen.com.

For Investor Inquiries:David DeLucia, CFAVice President of Corporate FP&A / Investor RelationsInvestorRelations@fibrogen.com

Primary Logo

Source: FibroGen, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com